Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
Max Gelman / endpoints - There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an approval, Atara said ...
AI Summary: Regulators have agreed to re-examine a previously rejected cell‑therapy application for a rare lymphoma, giving the Atara‑Pierre Fabre program another opportunity at approval. The decision follows additional data and stakeholder engagement, offering the developer a second bite at the apple and patients a renewed, if cautious, hope for a novel treatment pathway.
FDA approves blood test to guide breast cancer therapy
Ella Jeffries / beckershospitalreview - The FDA has approved a companion diagnostic from Guardant Health to identify patients eligible for treatment with a targeted therapy developed by Pfizer and Arvinas. The blood-based test detects ESR1 mutations in patients with estrogen receptor-positive, …
AI Summary: The FDA approved a blood‑based test to help guide breast cancer treatment selection, authorizing a diagnostic that identifies patients more likely to benefit from specific therapies. The move could reduce unnecessary treatments and sharpen precision oncology, though broad clinical adoption will depend on further validation, payer coverage and clinician trust.
- ESMO Breast highlights and expert commentary (4)
- FDA clearances reshape diagnostics and therapies (3)
- Liquid biopsy, mutations and treatment resistance (4)
- All Other Stories
ESMO Breast highlights and expert commentary
FDA clearances reshape diagnostics and therapies
Liquid biopsy, mutations and treatment resistance
All Other Stories
Amgen files update to Tavneos label as FDA escalates push to withdraw
Nicole DeFeudis / endpoints - Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA. The company filed a supplement on Wednesday that would add more information to the warning ...
AI Summary: Regulators have intensified scrutiny of Amgen’s Tavneos, weighing withdrawal amid safety and efficacy concerns. Amgen responded by filing a label update as the agency evaluates next steps, setting up a regulatory standoff that could alter patient access and the drug’s commercial fate while investigators review supporting trial data.
Vivek Subbiah: F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow! It’s Big news on Friday. F.D.A. Grants Early Access to Promising Drug for […]
AI Summary: The FDA has authorized early access to a promising experimental therapy for pancreatic cancer, opening an expanded‑access pathway so eligible patients can receive the drug before full approval. Regulators based the decision on encouraging early clinical signals of activity and manageable safety data, aiming to offer options for a disease with few effective treatments—because pancreatic cancer isn’t known for its patience.
- Daraxonrasib expanded access: FDA opens early pathway (6)
- Research advances: diagnostics and targeted therapies for pancreatic cancer (5)
- All Other Stories
Daraxonrasib expanded access: FDA opens early pathway
Research advances: diagnostics and targeted therapies for pancreatic cancer
All Other Stories
Court restricts abortion access across US by blocking mailing of mifepristone
abcnews - A federal appeals court has restricted access to one of the most common means of abortion in the U.S. by blocking the mailing of mifepristone
AI Summary: A federal appeals court has imposed new limits on distribution of mifepristone, blocking mail-order shipments and narrowing telehealth-based prescribing. The decision immediately complicates access for patients and clinicians who rely on remote care and pharmacy delivery, forcing last‑minute logistical changes, increased travel, and swift legal and policy responses as providers scramble to adapt.
- Appeals court halts mail and telehealth access (4)
- Clinical pivots and drug alternatives amid disruptions (3)
- Supreme Court temporarily restores mail access (5)
- All Other Stories
Appeals court halts mail and telehealth access
Clinical pivots and drug alternatives amid disruptions
Supreme Court temporarily restores mail access
All Other Stories
Matthew Kurian: ODAC Votes 6–3 Against Camizestrant Approval In SERENA-6
oncodaily - Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn: “Breaking: ODAC Votes 6-3 Against Camizestrant Approval […]
AI Summary: An FDA oncology advisory committee delivered a 6–3 vote against approval of camizestrant following review of the SERENA‑6 trial, flagging concerns about the data package and the drug’s claimed “new paradigm.” The panel’s negative recommendation raises serious regulatory and commercial uncertainty for AstraZeneca’s oral SERD program and its path forward.
- Implications for HR+/HER2- treatment landscape (3)
- ODAC rejects camizestrant approval (8)
- All Other Stories
Implications for HR+/HER2- treatment landscape
ODAC rejects camizestrant approval
All Other Stories
FDA Announced Two Major Milestones in Implementing Real-Time Clinical Trials
oncodaily - U.S. Food and Drug Administration (FDA) shared a post on LinkedIn: “Today, the FDA announced two major milestones in implementing real-time clinical trials: Successful Proofs-of-Concept: FDA unveiled proof-of-concept trials with […]
AI Summary: The FDA announced major steps to implement real‑time clinical trial review through a new research collaboration, aiming to accelerate data flow and regulatory oversight. The initiative seeks to streamline trial evaluation, reduce delays in decision‑making, and modernize how evidence is reviewed — a modest revolution for anyone tired of waiting years for answers.
- AI, data and digital tools modernizing clinical trials (3)
- Equity, ethics and patient access in clinical trials (4)
- FDA real-time trial launches with academic and industry partners (4)
- All Other Stories
AI, data and digital tools modernizing clinical trials
Equity, ethics and patient access in clinical trials
FDA real-time trial launches with academic and industry partners
All Other Stories
FDA backs 3 psychedelic drug studies for mental illness
Ella Ruder / beckershospitalreview - The FDA is issuing national priority vouchers to three companies studying psychedelic drugs to treat serious mental illness. The vouchers were issued to companies studying psilocybin for treatment-resistant depression and major depressive disorder as well…
AI Summary: The FDA announced a targeted push to accelerate clinical research into psychedelics for mental illness, issuing three commissioner vouchers to support rigorous trials of psychedelic therapies. The move aims to fast-track evidence generation under regulatory oversight, signalling growing agency willingness to explore unconventional treatments while keeping safety and trial standards squarely in view.
- FDA voucher push and federal policy shift (5)
- Psilocybin and brain science (4)
- Real-world use, safety and clinical readiness (3)
- All Other Stories
FDA voucher push and federal policy shift
Psilocybin and brain science
Real-world use, safety and clinical readiness
All Other Stories
CMS, FDA announce new program to speed up Medicare coverage of breakthrough medical devices
fiercehealthcare - The Trump administration unveiled a new program to speed up Medicare coverage for breakthrough devices, touting that the new pathway cuts red tape for medical device companies to gain reimbursement. CMS said it will pause the existing TCET pathway.
AI Summary: CMS and the Food and Drug Administration launched a coordinated program to accelerate Medicare coverage for breakthrough medical devices, aiming to shorten the gap between regulatory approval and patient access. The initiative aligns agency review processes, defines eligibility, and seeks faster coverage decisions while maintaining safety and evidentiary standards.
- New imaging and monitoring devices promise faster, remote patient care. (3)
- On scene: agencies align to speed device approvals and coverage. (6)
New imaging and monitoring devices promise faster, remote patient care.
On scene: agencies align to speed device approvals and coverage.
FDA approves 1st 2-drug HIV treatment
Ella Jeffries / beckershospitalreview - The FDA has approved Merck’s once-daily, two-drug regimen for adults with virologically suppressed HIV-1. The treatment combines 100 mg doravirine and 0.25 mg islatravir and is indicated for patients with no history of virologic treatment failure and no k…
AI Summary: The FDA has approved Merck’s once‑daily two‑drug antiretroviral regimen, marking a notable market entrant poised to compete with established single‑pill therapies. Regulators cleared the novel combination on efficacy and safety data, setting up potential shifts in prescribing, pricing and competition — and giving Gilead something new to grumble about.
Should you really trust health advice from an AI chatbot?
bbc - Abi has had very mixed results when asking a chatbot for guidance about her health issues.
AI Summary: Recent analyses and a hospital study reveal mainstream AI chatbots frequently provide incorrect or misleading medical guidance and miss initial diagnoses, posing real patient‑safety risks. The research shows these systems can fabricate facts, overconfidently assert dubious recommendations and fail to flag uncertainty, prompting calls for clinician oversight, clearer warnings and tighter evaluation before trusting bots with health decisions.
- Chatbots misdiagnose and confidently give dangerous medical advice (4)
- Companies race to build clinical AI tools and invest heavily (4)
- Other AI healthcare stories: innovation, payers, workflows, mental health trials (12)
- Researchers demand proof and robust evaluation before clinical AI deployment (5)
- Utah pilots bold AI medical programs, sparking safety debates (3)
- All Other Stories
Chatbots misdiagnose and confidently give dangerous medical advice
Companies race to build clinical AI tools and invest heavily
Other AI healthcare stories: innovation, payers, workflows, mental health trials
Researchers demand proof and robust evaluation before clinical AI deployment
Utah pilots bold AI medical programs, sparking safety debates
All Other Stories
FDA updates mifepristone safety study status
Ella Jeffries / beckershospitalreview - The FDA updated its mifepristone guidance, detailing ongoing work on a safety study and the current status of the drug’s Risk Evaluation and Mitigation Strategy program. According to an April 8 news release, the agency said it is still collecting and eval…
AI Summary: The FDA updated the safety review status for mifepristone, yet the regulatory change hasn’t translated into widespread retail availability. Many community pharmacies are still hesitant to dispense the drug due to logistical, legal and reputational concerns, leaving access limited despite federal moves intended to broaden distribution — so yes, policy changed, but practice lagged.
FDA approves Travere's Filspari as first drug for the kidney disease called FSGS
Nicole DeFeudis / endpoints - The FDA expanded the label for Filspari on Monday to add another kidney condition. The drug is now the first therapy approved in the US for focal segmental glomerulosclerosis (FSGS). The pill may be taken ...
AI Summary: The FDA approved Filspari for focal segmental glomerulosclerosis (FSGS), delivering the first specifically authorized treatment for this rare kidney disease. The approval provides a targeted therapeutic option for patients and marks a commercial milestone for Travere, raising hopes for better outcomes while spotlighting questions about access, pricing, and long‑term real‑world effectiveness.
One lot of Xanax recalled nationwide over quality issue, FDA says
medicalxpress - A widely used anxiety medication is being pulled from shelves due to "failed dissolution specifications," the U.S. Food and Drug Administration (FDA) said.
AI Summary: Regulators have flagged a quality issue and a manufacturer has recalled a specific lot of Xanax nationwide. Pharmacies and patients have been advised to check lot numbers and return affected pills; health officials emphasize the recall is precautionary, urging anyone with concerns to consult their pharmacist or clinician rather than panic-buy substitutes.
FDA to review whether to allow more access to certain peptides
medicalxpress - The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.
AI Summary: The FDA is moving toward expanding access to certain compounded peptides, opening a regulatory review that could loosen limits on how pharmacies and clinics obtain and prepare these popular therapies. The review balances potential patient demand and shortages against safety and quality-control concerns, putting compounding practices squarely under the spotlight.
Anti-amyloid Alzheimer's drugs show no clinically meaningful effect
medicalxpress - Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new review in the Cochrane Database of Systematic Reviews has found.
AI Summary: A major review concludes anti-amyloid Alzheimer’s medications show no clinically meaningful effect on patients’ cognition or daily function, prompting renewed debate about drug approvals, prescribing and research priorities. The analysis calls for careful reassessment of treatment value, clearer communication to patients and tighter scrutiny of future trials.
- Anti-amyloid drugs fall short: little benefit, safety risks (5)
- New biomarkers and imaging reshape Alzheimer’s diagnosis timing (3)
- Social and care issues: loneliness, memory and treatment decisions (2)
- All Other Stories
Anti-amyloid drugs fall short: little benefit, safety risks
New biomarkers and imaging reshape Alzheimer’s diagnosis timing
Social and care issues: loneliness, memory and treatment decisions
All Other Stories
New drug doubles 1-year survival in pancreatic cancer trial
medicalxpress - Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.
AI Summary: A Phase 3 study showed a novel agent markedly lengthened survival for people with metastatic pancreatic cancer, roughly doubling one-year survival versus standard care. The results, from the RASolute 302 program evaluating daraxonrasib/Revolution Medicines’ approach, represent an uncommon advance in a stubbornly lethal disease and could change treatment standards pending regulatory review.
- Clinicians celebrate landmark KRAS win; cautious optimism prevails (7)
- Daraxonrasib Phase 3: drug doubles one-year survival (5)
- Market scramble: Revolution Medicines' fundraising and buyout buzz (3)
- Other pancreatic research, methods and early-stage KRAS studies (5)
- All Other Stories
Clinicians celebrate landmark KRAS win; cautious optimism prevails
Daraxonrasib Phase 3: drug doubles one-year survival
Market scramble: Revolution Medicines' fundraising and buyout buzz
Other pancreatic research, methods and early-stage KRAS studies
All Other Stories
FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
esmo - Evidence for efficacy is based on the findings from the ROSELLA study
AI Summary: The FDA granted marketing authorization for relacorilant in combination with nab‑paclitaxel to treat platinum‑resistant epithelial ovarian, fallopian tube and primary peritoneal cancers. Regulators cited clinical benefit in a difficult‑to‑treat population, providing an additional therapeutic option for patients with limited choices and marking an important regulatory milestone.
RFK Jr. launching health podcast to expose ‘hypocrisy’ and ‘corruption’
fiercehealthcare - Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services (HHS) secretary framed the podcast as a response to public health problems that he said have made “many of us ... come to the conc…
AI Summary: Robert F. Kennedy Jr. is debuting a health-focused podcast promising to call out what he characterizes as hypocrisy and corruption in medicine and public health. The show aims to amplify skeptical takes on mainstream health institutions and policies, positioning itself as a combative platform for contrarian voices and investigations.
FDA identifies eight deaths tied to Amgen's Tavneos
Max Bayer / endpoints - The FDA on Tuesday flagged more than 70 cases of severe liver injury and eight deaths associated with Amgen’s autoimmune treatment Tavneos, but the company said it previously notified the agency about the risk of ...
AI Summary: The FDA has tied eight patient deaths to Amgen’s drug Tavneos, prompting heightened regulatory review and industry concern. Reports outline safety signals and agency actions as clinicians and manufacturers reassess risk‑benefit profiles, while regulators weigh labeling, monitoring or other interventions to protect patients.